Home - Products - Angiogenesis - EGFR - Tyrphostin B44, (+) enantiomer

Tyrphostin B44, (+) enantiomer

CAS No. 133550-37-5

Tyrphostin B44, (+) enantiomer( —— )

Catalog No. M23490 CAS No. 133550-37-5

Tyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 0.86 μM and has less active than the (-) enantiomer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 79 In Stock
5MG 71 In Stock
10MG 111 In Stock
25MG 193 In Stock
50MG 259 In Stock
100MG 372 In Stock
200MG 505 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tyrphostin B44, (+) enantiomer
  • Note
    Research use only, not for human use.
  • Brief Description
    Tyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 0.86 μM and has less active than the (-) enantiomer.
  • Description
    Tyrphostin B44, (+) enantiomer is an inhibitor of epidermal growth factor receptor (EGFR) kinase with IC50 of 0.86 μM and has less active than the (-) enantiomer.
  • In Vitro
    (+)-Tyrphostin B44 (Tyrphostin AG 835) (Compound B50) (0-100 μM) inhibits cell survival with EC50 values of 3.12, 12.5 and 12.5 μM against CALO, INBL and HeLa cells, respectively.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    133550-37-5
  • Formula Weight
    308.33
  • Molecular Formula
    C18H16N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 100 mg/mL (324.33 mM)
  • SMILES
    C[C@@H](c1ccccc1)NC(/C(/C#N)=C/c(cc1)cc(O)c1O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • EGFR-IN-1 hydrochlor...

    EGFR-IN-1 hydrochloride is an irreversible and specific inhibitor of L858R/T790M mutant EGFR, with 100-fold selectivity over wild-type EGFR.

  • Allitinib

    Allitinib (AST-1306) has anti-cancer activity,and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively.

  • Theliatinib

    Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.